Normoblastemia in COVID-19 patients is associated with more severe disease and adverse outcome.

IF 1.1 Q4 ONCOLOGY

International journal of clinical and experimental pathology Pub Date : 2023-09-15 eCollection Date: 2023-01-01

Kenneth Ofori, Diane Chen, Jorge Sepulveda, Govind Bhagat, Bachir Alobeid

{"title":"Normoblastemia in COVID-19 patients is associated with more severe disease and adverse outcome.","authors":"Kenneth Ofori, Diane Chen, Jorge Sepulveda, Govind Bhagat, Bachir Alobeid","doi":"","DOIUrl":null,"url":null,"abstract":"Objectives: The clinical, pathological, and laboratory correlates of normoblastemia in COVID-19 patients have not been adequately explored. We sought to assess the frequency of normoblastemia in COVID-19, its association with other markers of disease, as well as other clinical outcomes.Methods: All COVID-19 patients seen at our institution with at least one automated complete blood count (aCBC) evaluation from March to May 2020 were included in this retrospective cohort analysis. Results of aCBC and tests for markers of the acute phase response performed within 5 days before the first COVID-19 positive test and 14 days after the last positive test were reviewed. We also evaluated histologic features of the reticuloendothelial system of COVID-19 decedents.Results: Among a total of 2501 COVID-19 patients, 715 (28.6%) were found to have normoblastemia. Patients with this abnormality had significantly higher (median, (1st quartile, 3rd quartile) WBC (15.7 (11.2, 23.1) u/L vs. 8.3 (6.2, 11.5) u/L), absolute neutrophil count (7.0 (5.1, 10.1) u/L vs. 5.1 (3.7, 7.3) u/L), immature granulocyte percentage (0.8 (0.5, 1.3)% vs. 0.5 (0.3, 0.8)%), ESR (76.0 (60.5, 100.0) mm/hr vs. 66.0 (45.0, 87.0) mm/hr), ferritin (1404.5 (645.0, 2871.0) ng/mL vs. 672.7 (313.4, 1348.0) ng/mL), INR (1.4 (1.2, 1.7) vs. 1.2 (1.1, 1.3)), D-dimer (8.2 (2.8, 20.0) ug/mL FEU vs. 1.5 (0.8, 3.7) µg/mL FEU), and IL-6 (216.6 (77.7, 315.0) pg/mL vs. 54.3 (23.2, 127.8) pg/mL) levels, and lower hemoglobin (12.5 (10.7, 14.2) g/dL vs. 13.2 (11.8, 14.6) g/dL) and absolute lymphocyte count (1.0 (0.7, 1.3) u/L vs. 1.1 (0.8, 1.5) u/L). The incidence of intubation and ventilation support (61.3% (65/106) vs. 10.5% (31/263)) and mortality rates (37.9%, 271/715 vs. 11.8%, 210/1786), were higher in normoblastemic patients. Multivariable logistic regression revealed normoblastemia to be an independent predictive biomarker of short-term mortality in COVID-19.Conclusion: Normoblastemia in COVID-19 is associated with markers of severe disease, extramedullary erythropoiesis, and adverse clinical outcome.","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"16 9","pages":"235-242"},"PeriodicalIF":1.1000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560885/pdf/ijcep0016-0235.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical and experimental pathology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The clinical, pathological, and laboratory correlates of normoblastemia in COVID-19 patients have not been adequately explored. We sought to assess the frequency of normoblastemia in COVID-19, its association with other markers of disease, as well as other clinical outcomes.

Methods: All COVID-19 patients seen at our institution with at least one automated complete blood count (aCBC) evaluation from March to May 2020 were included in this retrospective cohort analysis. Results of aCBC and tests for markers of the acute phase response performed within 5 days before the first COVID-19 positive test and 14 days after the last positive test were reviewed. We also evaluated histologic features of the reticuloendothelial system of COVID-19 decedents.

Results: Among a total of 2501 COVID-19 patients, 715 (28.6%) were found to have normoblastemia. Patients with this abnormality had significantly higher (median, (1^st quartile, 3^rd quartile) WBC (15.7 (11.2, 23.1) u/L vs. 8.3 (6.2, 11.5) u/L), absolute neutrophil count (7.0 (5.1, 10.1) u/L vs. 5.1 (3.7, 7.3) u/L), immature granulocyte percentage (0.8 (0.5, 1.3)% vs. 0.5 (0.3, 0.8)%), ESR (76.0 (60.5, 100.0) mm/hr vs. 66.0 (45.0, 87.0) mm/hr), ferritin (1404.5 (645.0, 2871.0) ng/mL vs. 672.7 (313.4, 1348.0) ng/mL), INR (1.4 (1.2, 1.7) vs. 1.2 (1.1, 1.3)), D-dimer (8.2 (2.8, 20.0) ug/mL FEU vs. 1.5 (0.8, 3.7) µg/mL FEU), and IL-6 (216.6 (77.7, 315.0) pg/mL vs. 54.3 (23.2, 127.8) pg/mL) levels, and lower hemoglobin (12.5 (10.7, 14.2) g/dL vs. 13.2 (11.8, 14.6) g/dL) and absolute lymphocyte count (1.0 (0.7, 1.3) u/L vs. 1.1 (0.8, 1.5) u/L). The incidence of intubation and ventilation support (61.3% (65/106) vs. 10.5% (31/263)) and mortality rates (37.9%, 271/715 vs. 11.8%, 210/1786), were higher in normoblastemic patients. Multivariable logistic regression revealed normoblastemia to be an independent predictive biomarker of short-term mortality in COVID-19.

Conclusion: Normoblastemia in COVID-19 is associated with markers of severe disease, extramedullary erythropoiesis, and adverse clinical outcome.

本刊更多论文

新冠肺炎患者的Normoblastemia与更严重的疾病和不良后果相关。

目的：尚未充分探讨新冠肺炎患者正常血细胞的临床、病理和实验室相关性。我们试图评估新冠肺炎中正常血细胞的频率、其与其他疾病标志物的关系以及其他临床结果。方法：将2020年3月至5月在我们机构就诊的所有新冠肺炎患者纳入本回顾性队列分析，这些患者至少进行了一次自动全血细胞计数（aCBC）评估。回顾首次新冠肺炎阳性检测前5天和最后一次阳性检测后14天内进行的aCBC结果和急性期反应标志物检测。我们还评估了新冠肺炎死者网状内皮系统的组织学特征。结果：在总共2501名新冠肺炎患者中，715人（28.6%）的血细胞正常。有这种异常的患者具有显著更高的（中位数，（第一个四分位数，第三个四分位）WBC（15.7（11.2，23.1）u/L vs.8.3（6.2，11.5）u/L），中性粒细胞绝对计数（7.0（5.1，10.1）u/L vs 5.1（3.7，7.3）u/L，未成熟粒细胞百分比（0.8（0.5，1.3）%vs.0.5（0.3，0.8）%），ESR（76.0（60.5，100.0）mm/hr vs.66.0（45.0，87.0）mm/hr），铁蛋白（1404.5（645.02871.0）ng/mL vs.672.7（313.41348.0）ng/mL）、INR（1.4（1.2，1.7）vs.1.2（1.1，1.3））、D-二聚体（8.2（2.8，20.0）ug/mL FEU vs.1.5（0.8，3.7）µg/mL FEU）和IL-6（216.6（77.7315.0）pg/mL vs.54.3（23.2127.8）pg/mL）水平，血红蛋白（12.5（10.7，14.2）g/dL对13.2（11.8，14.6）g/dL）和绝对淋巴细胞计数（1.0（0.7，1.3）u/L对1.1（0.8，1.5）u/L）较低。插管和通气支持的发生率（61.3%（65/106）对10.5%（31/263））和死亡率（37.9%，271/715对11.8%，210/1786）在正常血细胞患者中较高。多因素逻辑回归显示，正常血细胞是COVID-19短期死亡率的独立预测生物标志物。结论：COVID-19]中的正常血细胞与严重疾病、髓外红细胞生成和不良临床结果的标志物相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of clinical and experimental pathology ONCOLOGY-PATHOLOGY

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： The International Journal of Clinical and Experimental Pathology (IJCEP, ISSN 1936-2625) is a peer reviewed, open access online journal. It was founded in 2008 by an international group of academic pathologists and scientists who are devoted to the scientific exploration of human disease and the rapid dissemination of original data. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal.